Annual CFO
-$92.17 M
-$65.39 M-244.27%
31 December 2023
Summary:
Poseida Therapeutics annual cash flow from operations is currently -$92.17 million, with the most recent change of -$65.39 million (-244.27%) on 31 December 2023. During the last 3 years, it has risen by +$21.16 million (+18.67%). PSTX annual CFO is now -306.08% below its all-time high of -$22.70 million, reached on 31 December 2017.PSTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$9.59 M
-$48.04 M-124.95%
30 September 2024
Summary:
Poseida Therapeutics quarterly cash flow from operations is currently -$9.59 million, with the most recent change of -$48.04 million (-124.95%) on 30 September 2024. Over the past year, it has dropped by -$17.48 million (-221.63%). PSTX quarterly CFO is now -115.50% below its all-time high of $61.88 million, reached on 30 September 2022.PSTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$15.02 M
-$17.48 M-710.94%
30 September 2024
Summary:
Poseida Therapeutics TTM cash flow from operations is currently -$15.02 million, with the most recent change of -$17.48 million (-710.94%) on 30 September 2024. Over the past year, it has increased by +$46.00 million (+75.38%). PSTX TTM CFO is now -710.94% below its all-time high of $2.46 million, reached on 30 June 2024.PSTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -244.3% | -221.6% | +75.4% |
| 3 y3 years | +18.7% | +76.5% | +89.4% |
| 5 y5 years | -142.5% | +50.0% | +68.7% |
PSTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -244.3% | +18.7% | -115.5% | +81.3% | -710.9% | +89.4% |
| 5 y | 5 years | -244.3% | +18.7% | -115.5% | +81.3% | -710.9% | +89.4% |
| alltime | all time | -306.1% | +18.7% | -115.5% | +81.3% | -710.9% | +89.4% |
Poseida Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.59 M(-125.0%) | -$15.02 M(-710.9%) |
| June 2024 | - | $38.45 M(-354.0%) | $2.46 M(-103.5%) |
| Mar 2024 | - | -$15.13 M(-47.3%) | -$69.30 M(-24.8%) |
| Dec 2023 | -$92.17 M(+244.3%) | -$28.74 M(-464.4%) | -$92.17 M(+51.0%) |
| Sept 2023 | - | $7.89 M(-123.7%) | -$61.02 M(+768.0%) |
| June 2023 | - | -$33.31 M(-12.4%) | -$7.03 M(-47.7%) |
| Mar 2023 | - | -$38.01 M(-1681.6%) | -$13.45 M(-49.7%) |
| Dec 2022 | -$26.77 M(-73.9%) | $2.40 M(-96.1%) | -$26.77 M(+29.3%) |
| Sept 2022 | - | $61.88 M(-255.8%) | -$20.70 M(-83.2%) |
| June 2022 | - | -$39.73 M(-22.6%) | -$123.45 M(+7.5%) |
| Mar 2022 | - | -$51.32 M(-705.7%) | -$114.81 M(+12.0%) |
| Dec 2021 | -$102.54 M | $8.47 M(-120.7%) | -$102.54 M(-27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$40.87 M(+31.5%) | -$141.33 M(+8.9%) |
| June 2021 | - | -$31.09 M(-20.4%) | -$129.79 M(+0.2%) |
| Mar 2021 | - | -$39.06 M(+28.8%) | -$129.50 M(+14.3%) |
| Dec 2020 | -$113.33 M(+75.7%) | -$30.32 M(+3.4%) | -$113.33 M(+13.8%) |
| Sept 2020 | - | -$29.33 M(-4.8%) | -$99.58 M(+11.4%) |
| June 2020 | - | -$30.80 M(+34.6%) | -$89.42 M(+22.9%) |
| Mar 2020 | - | -$22.89 M(+38.2%) | -$72.74 M(+12.7%) |
| Dec 2019 | -$64.52 M(+69.7%) | -$16.56 M(-13.6%) | -$64.52 M(+34.5%) |
| Sept 2019 | - | -$19.17 M(+35.8%) | -$47.95 M(+66.6%) |
| June 2019 | - | -$14.12 M(-3.7%) | -$28.78 M(+96.3%) |
| Mar 2019 | - | -$14.66 M | -$14.66 M |
| Dec 2018 | -$38.01 M(+67.5%) | - | - |
| Dec 2017 | -$22.70 M | - | - |
FAQ
- What is Poseida Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Poseida Therapeutics?
- What is Poseida Therapeutics annual CFO year-on-year change?
- What is Poseida Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly CFO year-on-year change?
- What is Poseida Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Poseida Therapeutics?
- What is Poseida Therapeutics TTM CFO year-on-year change?
What is Poseida Therapeutics annual cash flow from operations?
The current annual CFO of PSTX is -$92.17 M
What is the all time high annual CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high annual cash flow from operations is -$22.70 M
What is Poseida Therapeutics annual CFO year-on-year change?
Over the past year, PSTX annual cash flow from operations has changed by -$65.39 M (-244.27%)
What is Poseida Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PSTX is -$9.59 M
What is the all time high quarterly CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly cash flow from operations is $61.88 M
What is Poseida Therapeutics quarterly CFO year-on-year change?
Over the past year, PSTX quarterly cash flow from operations has changed by -$17.48 M (-221.63%)
What is Poseida Therapeutics TTM cash flow from operations?
The current TTM CFO of PSTX is -$15.02 M
What is the all time high TTM CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high TTM cash flow from operations is $2.46 M
What is Poseida Therapeutics TTM CFO year-on-year change?
Over the past year, PSTX TTM cash flow from operations has changed by +$46.00 M (+75.38%)